http://jcps.bjmu.edu.cn

• 研究论文 • 上一篇    下一篇

HPLC法测定人血浆和尿中尼扎替丁浓度及药动学研究

张玲, 赵艳萍, 乔华, 王婷*, 梁莉, 常威, 李丹, 徐培涵

  

  1. 1. 兰州大学 药学院, 甘肃 兰州 730000
    2. 兰州大学 第一医院药剂科 药理基地, 甘肃 兰州 730000
  • 收稿日期:2010-02-15 修回日期:2010-06-10 出版日期:2010-07-15 发布日期:2010-07-15
  • 通讯作者: 王婷*

Quantitative determination of nizatidine in human plasma and urine by high performance liquid chromatography and its pharmacokinetic study in humans

Ling Zhang, Yan-Ping Zhao, Hua Qiao, Ting Wang*, Li Liang, Wei Chang, Dan Li, Pei-Han Xu

  

  1. 1. School of Pharmacy, Lanzhou University, Lanzhou 730000, China
    2. Department of Pharmacy, the First Hospital of Lanzhou University, Lanzhou 730000, China
  • Received:2010-02-15 Revised:2010-06-10 Online:2010-07-15 Published:2010-07-15
  • Contact: Ting Wang*

摘要:

建立了反相高效液相色谱法测定人血浆及尿中尼扎替丁浓度, 并进行健康人体药动学研究。色谱柱为Diamonsil C18柱, 流动相为乙腈-0.05 mol/L磷酸氢二钾-三乙胺 (17:83:1, v/v/v, pH 6.5), 流速0.9 mL/min, 紫外波长320 nm。10名健康志愿者 (男女各半) 单次静脉滴注尼扎替丁100 mg和多次给药 (100 mg/次, 3次/日, 连用6天)后, 测定尼扎替丁血样及尿样浓度, DAS软件计算药动学参数。血浆药物浓度在 (0.0117-6) mg/mL范围内具良好线性关系 (r = 0.9999), 尿中药物浓度在(0.029-50) µg/mL范围内呈良好线性关系 (r = 0.9998), 定量下限为0.0117 µg/mL, 日内、日间精密度分别低于5.12% 和 8.03% (血样), 6.2%和6.9% (尿样)。尼扎替丁主要药动学参数为: 单剂量: Cmax (2.7±0.6) µg/mL, t1/2 (1.4±0.4) h, AUC0-12h (2.45±0.33) μg·h/mL, AUC0-∞ (2.46±0.33) μg·h/mL, 12小时尿累计排泄率为61.2%±9.46%; 多剂量: Cmax (2.9±0.8) µg/mL, t1/2 (1.3±0.2) h, AUC0-12h (2.56±0.52) μg·h/mL, AUC0-∞ (2.56±0.52) μg·h/mL, 12小时尿累计排泄率为51.3%±9.42%。对单剂量、多剂量及性别的药代动力学参数进行比较, 结果差异无显著性差异。多次给药体内无蓄积。该法简便、快捷、灵敏、准确, 适用于尼扎替丁药代动力学研究。

关键词: 尼扎替丁, 高效液相色谱, 药动学

Abstract: A validated simple and sensitive high performance liquid chromatographic (HPLC) method for the quantitative determination of nizatidine (NIZ) in human plasma and urine is reported. Reverse phase chromatographic separation of NIZ and salicylic acid (internal standard) was achieved on Diamonsil C18 column, using acetonitrile-0.05 mol/L K2HPO4-triethylamine (17:83:1, v/v/v, pH 6.5) as the mobile phase. Flow rate was 0.9 mL/min and the ultraviolet detector was set at a wavelength of 320 nm. The assay was linear over the range of 0.0117-6 mg/mL for plasma samples and 0.029-50 µg/mL for urine samples. The limit of quantification was 0.0117 μg/mL. The intra- and inter-day RSD values were lower than 5.12% and 8.03%, respectively, in plasma, and 6.2% and 6.9%, respectively, in urine. A single dose of 100 mg NIZ and multiple doses of 100 mg NIZ were administered to 10 healthy volunteers through intravenous infusions. The multiple dose regimens were administered every 8 h for 6 consecutive days. The pharmacokinetic parameters were obtained as following: for single-dose, Cmax (2.7±0.6) µg/mL, t1/2 (1.4±0.4) h, AUC0-12h (2.45±0.33) μg·h/mL, AUC0-∞ (2.46±0.33) μg·h/mL, and the accumulated urine excretion rate in 12 h was 61.2%±9.46%; for multiple doses, Cmax (2.9±0.8) µg/mL, t1/2 (1.3±0.2) h, AUC0-12h (2.56±0.52) μg·h/mL, AUC0-(2.56±0.52) μg·h/mL, and the accumulated urine excretion rate in 12 h was 51.3%±9.42%. The statistical analysis of the pharmacokinetic parameters in males and females after single-dose and multiple-dose intravenous infusion of NIZ showed no differences. No drug accumulation after multiple-dose intravenous infusion of 100 mg NIZ was observed. The validated HPLC method was suitable for the pharmacokinetic study of NIZ.

Key words: Nizatidine, RP-HPLC, Pharmacokinetics

中图分类号: 

Supporting:

*Corresponding author. Tel.: 86-931-8625200-6748